AlphaCentric Advisors’s Celldex Therapeutics CLDX Stock Holding History

AlphaCentric Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$476K	Buy	12,784 +170	+1%	+$5.49K	0.4%	91
2026 Q1	$400K	Buy	+12,614	New	+$344K	0.4%	87
2024 Q4	–	Sell	-30,000	Closed	-$1.02M	–	224
2024 Q3	$1.02M	Sell	30,000 -17,500	-37%	-$667K	0.76%	44
2024 Q2	$1.76M	Buy	47,500 +9,000	+23%	+$340K	1.29%	19
2024 Q1	$1.62M	Buy	+38,500	New	+$1.58M	0.97%	32
2023 Q4	–	Sell	-15,000	Closed	-$413K	–	237
2023 Q3	$413K	Hold	15,000	–	–	0.23%	97
2023 Q2	$509K	Hold	15,000	–	–	0.28%	95
2023 Q1	$540K	Hold	15,000	–	–	0.37%	84
2022 Q4	$669K	Sell	15,000 -2,000	-12%	-$71.4K	0.66%	56
2022 Q3	$478K	Buy	+17,000	New	+$521K	0.49%	57
2021 Q4	$657K	Hold	17,000	–	–	0.19%	54
2021 Q3	$918K	Sell	17,000 -8,000	-32%	-$375K	0.23%	37
2021 Q2	$836K	Hold	25,000	–	–	0.23%	34
2021 Q1	$515K	Buy	25,000 +21,500	+614%	+$494K	0.17%	43
2020 Q4	$61K	Hold	3,500	–	–	0.03%	170
2020 Q3	$52K	Buy	+3,500	New	+$41K	0.03%	104

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCentric Advisors's CLDX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Celldex Therapeutics (CLDX) stake by 1.3% in Q2 2026, buying an estimated $5.49K and bringing the position to 12,784 shares worth $476K. The position accounts for 0.4% of the portfolio, ranked #91.

AlphaCentric Advisors first reported a position in CLDX in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.76M in Q2 2024. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

AlphaCentric Advisors held 12,784 shares of Celldex Therapeutics worth $476K as of Q2 2026.
AlphaCentric Advisors bought 170 Celldex Therapeutics shares in Q2 2026, an estimated $5.49K.
Celldex Therapeutics made up 0.4% of AlphaCentric Advisors's portfolio in Q2 2026, its #91 holding.
AlphaCentric Advisors first reported a position in Celldex Therapeutics in Q3 2020 and has held it in 16 quarters since.
AlphaCentric Advisors's Celldex Therapeutics position peaked at $1.76M in Q2 2024.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.